Awaiting development: Guidance and quality standards

Showing 61 to 70 of 307

Guidance and quality standards awaiting development
Title	Type
Datopotamab deruxtecan with durvalumab for treating triple-negative breast cancer when there is residual invasive disease after neoadjuvant systemic treatment and surgery [TSID12242]	Technology appraisal guidance
Decitabine–cedazuridine with venetoclax for treating acute myeloid leukaemia when induction chemotherapy is unsuitable [ID6601]	Technology appraisal guidance
Delgocitinib for Chronic Hand Eczema [ID12188]	Technology appraisal guidance
Denosumab biosimilar for Giant cell-rich tumours of bone or Skeletal events in bone malignancies ID12150	Technology appraisal guidance
Deucravacitinib for treating active psoriatic arthritis [TSID11981]	Technology appraisal guidance
Dexamethasone intracanalicular insert for treating inflammation and pain after cataract surgery [ID1154]	Technology appraisal guidance
Digital hearing aids	Health technology evaluation
Digital technologies for multidisciplinary weight management	Health technology evaluation
Domvanalimab with zimberelimab for untreated unresectable advanced gastric, gastro-oesophageal junction or oesophageal cancer [ID6606]	Technology appraisal guidance
Dorocubicel for treating haematological cancer when a suitable donor is unavailable for an allogeneic haematopoietic stem cell transplant [ID6521]	Technology appraisal guidance